Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal contrast-enhanced MRI for investigation of cerebrospinal fluid transportation
2024-520146-33-00Phase 2Authorised
- Sponsor
- Region Västerbotten
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gadobutrol in Idiopathic Normal Pressure Hydrocephalus (NPH), Alzheimer's disease (AD) and Cerebrospinal fluid circulation disorder (3 arms), sponsored by Region Västerbotten. Planned start Jan 2025; status: authorised.
02
Drugs
gadobutrol
03
Conditions
Idiopathic Normal Pressure Hydrocephalus (NPH)Alzheimer's disease (AD)Cerebrospinal fluid circulation disorder
Beyond the preview
Go deeper on 2024-520146-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520146-33-00.